Buy — Pfizer Stock

For , Pfizer may remain a "dead money" asset due to the lack of immediate revenue drivers. However, for long-term value and income investors , the stock offers a rare combination of a high, sustainable yield and the potential for a significant "re-rating" once the market gains confidence in its post-2028 growth engine.

: Official 2026 guidance forecasts revenue between $59.5 billion and $62.5 billion , a slight decline from 2025 levels. This "soft" outlook has led many major brokerages, such as Bank of America and Bernstein , to maintain "Neutral" or "Hold" ratings. buy pfizer stock

As of April 2026, the case for buying Pfizer (PFE) stock centers on its status as a "deep value" play with a high dividend yield, contrasted against significant mid-term revenue headwinds. Following its late-2025 financial guidance, which projected flat to slightly declining revenue for 2026, the stock has traded at a significant discount to its historical norms and the broader S&P 500. For , Pfizer may remain a "dead money"

: Pfizer anticipates a $1.5 billion revenue headwind in 2026 due to patent expirations, with these losses projected to accelerate to over $6 billion annually by 2028 . This "soft" outlook has led many major brokerages,